跳至主要内容
临床试验/NCT00137410
NCT00137410已完成3 期

Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee

Pfizer17 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2002年11月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
200
试验地点
17
主要终点
Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare

研究概览

简要总结

This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
  • patients in flare

排除标准

  • any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
  • clinical or radiological evidence of chondrocalcinosis

结局指标

主要结局

Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare

次要结局

  • Flare intensity WOMAC OA index Psycho-affective Index Pt's assessment of OA pain (VAS) Pt's & Physician's global assessment disease severity Incidence of total AEs Incidence of GI AEs: Incidence of changes in: hematology, renal function, liver function

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (17)

Loading locations...

相似试验